MedTrace Logo

Hair Regeneration in Androgenetic Alopecia

NCT06066827 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-10-10

No results posted yet for this study

Summary

This clinical trial study aims to compare the effectiveness and safety of secretome from ADSCs with minoxidil in AGA cases, to provide future reference or standard in the application of cell-based therapy and its derivatives in AGA cases. The subject of this study is androgenetic alopecia population. The main questions it aims to answer are:

* Is the secretome of ADSC's effective compared to minoxidil?
* Is the secretome of ADSC's safe compared to minoxidil?
* Is the combination of the secretome of ADSC's and minoxidil better in safety and effectiveness compared to secretome or minoxidil alone?

Conditions

Interventions

DRUG

Minoxidil Topical

20 subjects received minoxidil only for the treatment of AGA

OTHER

Secretome from adipose-derived stem cells

20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA

COMBINATION_PRODUCT

Combination of minoxidil and secretome from adipose-derived stem cells

20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA

Sponsors & Collaborators

  • Ministry of Education, Culture, Research, and Technology, Republic of Indonesia

    collaborator UNKNOWN

  • PT. Kimia Farma (Persero) Tbk

    collaborator INDUSTRY

  • Dr. dr. Lili Legiawati, SpKK(K)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-14
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06066827 on ClinicalTrials.gov